UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Enhancing human resilience beyond COVID-19-related stress: public responses to multi-benefits of home gardening

Scientific reports, 2023-06, Vol.13 (1), p.10534-10534, Article 10534

2023

Volltextzugriff (PDF)

Analysis of Unidirectional Absorption in a Defective Superconducting Photonic Crystal

IEEE photonics journal, 2017-08, Vol.9 (4), p.1-9

2017

Volltextzugriff (PDF)

Terahertz transmission properties of a triadic-Cantor-set photonic crystal containing a semiconductor

Optics communications, 2016-08, Vol.372, p.91-97

2016

Volltextzugriff (PDF)

Wave properties in asymmetric single-negative-base photonic crystals

Applied optics (2004), 2017-12, Vol.56 (34), p.9452

2017

Volltextzugriff (PDF)

Perceived COVID-19-related stress drives home gardening intentions and improves human health in Taiwan

Urban forestry & urban greening, 2022-12, Vol.78, p.127770, Article 127770

2022

Volltextzugriff (PDF)

The Golden Champion

Huang, Hsi-Chih Philip

1997

Volltextzugriff (PDF)

Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation

International journal of cancer, 2022-02, Vol.150 (4), p.626-635

2022

Volltextzugriff (PDF)

The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis

Scientific reports, 2022-03, Vol.12 (1), p.4398-4398, Article 4398

2022

Volltextzugriff (PDF)

Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

BMC cancer, 2021-07, Vol.21 (1), p.1-859, Article 859

2021

Volltextzugriff (PDF)

Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer

Thoracic cancer, 2020-06, Vol.11 (6), p.1541-1549

2020

Volltextzugriff (PDF)

Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer

Thoracic cancer, 2024-03, Vol.15 (7), p.529-537

2024

Volltextzugriff (PDF)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Scientific reports, 2023-11, Vol.13 (1), p.20323-20323, Article 20323

2023

Volltextzugriff (PDF)

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan

Thoracic cancer, 2023-01, Vol.14 (1), p.12-23

2023

Volltextzugriff (PDF)

Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma

Journal of thoracic oncology, 2018-07, Vol.13 (7), p.958-967

2018

Volltextzugriff (PDF)

First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer

Therapeutic advances in medical oncology, 2021, Vol.13, p.17588359211035710-17588359211035710

2021

Volltextzugriff (PDF)

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients

Thoracic cancer, 2022-07, Vol.13 (13), p.1888-1897

2022

Volltextzugriff (PDF)

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors

Frontiers in oncology, 2023-10, Vol.13, p.1249106-1249106

2023

Volltextzugriff (PDF)

Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations

Therapeutic advances in respiratory disease, 2022, Vol.16, p.17534666221132731-17534666221132731

2022

Volltextzugriff (PDF)

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma

Cancers, 2022-01, Vol.14 (3), p.674

2022

Volltextzugriff (PDF)

Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations

Anticancer research, 2022-04, Vol.42 (4), p.2145-2157

2022

Volltextzugriff (PDF)

The survival after discontinuation of EGFR‐TKIs due to intolerable adverse events in patients with EGFR‐mutated non–small cell lung cancer

Thoracic cancer, 2023-02, Vol.14 (4), p.348-356

2023

Volltextzugriff (PDF)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinib

Thoracic cancer, 2023-09, Vol.14 (25), p.2548-2557

2023

Volltextzugriff (PDF)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study

Pharmaceuticals (Basel, Switzerland), 2020-10, Vol.13 (11), p.331

2020

Volltextzugriff (PDF)

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study

Therapeutic advances in medical oncology, 2022, Vol.14, p.17588359221113278-17588359221113278

2022

Volltextzugriff (PDF)

A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

BMC cancer, 2021-03, Vol.21 (1), p.309-309, Article 309

2021

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(53)

Publikationsform

Sprache

Englisch
(56)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Enhancing human resilience beyond COVID-19-related stress: public responses to multi-benefits of home gardening

Analysis of Unidirectional Absorption in a Defective Superconducting Photonic Crystal

Terahertz transmission properties of a triadic-Cantor-set photonic crystal containing a semiconductor

Wave properties in asymmetric single-negative-base photonic crystals

Perceived COVID-19-related stress drives home gardening intentions and improves human health in Taiwan

The Golden Champion

Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation

The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis

Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer

Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan

Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma

First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors

Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma

Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations

The survival after discontinuation of EGFR‐TKIs due to intolerable adverse events in patients with EGFR‐mutated non–small cell lung cancer

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinib

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study

A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

Suchergebnisse filtern